EGFR and non-small cell lung carcinoma: EGFR inhibitors have shown promise and extended patient survival in lung, pancreatic and other cancers, however, survival gains are often modest, and, in non-small-cell lung cancers, activity is limited to the approximately 10% of patients with small activating mutations in the EGFR tyrosine kinase domain [2,3].